PDT Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-3,484
| Closed | -$958K | – | 707 |
|
|
2024
Q3 | $958K | Sell |
3,484
-10,800
| -76% | -$2.97M | 0.08% | 374 |
|
|
2024
Q2 | $3.47M | Buy |
+14,284
| New | +$3.47M | 0.33% | 86 |
|
|
2024
Q1 | – | Sell |
-5,916
| Closed | -$1.13M | – | 621 |
|
|
2023
Q4 | $1.13M | Sell |
5,916
-8,551
| -59% | -$1.64M | 0.13% | 268 |
|
|
2023
Q3 | $2.56M | Buy |
+14,467
| New | +$2.56M | 0.32% | 91 |
|
|
2021
Q1 | – | Sell |
-8,800
| Closed | -$1.14M | – | 761 |
|
|
2020
Q4 | $1.14M | Buy |
+8,800
| New | +$1.14M | 0.08% | 303 |
|
|
2020
Q2 | – | Sell |
-68,313
| Closed | -$7.44M | – | 659 |
|
|
2020
Q1 | $7.44M | Sell |
68,313
-48,700
| -42% | -$5.3M | 0.59% | 50 |
|
|
2019
Q4 | $13.5M | Sell |
117,013
-5,100
| -4% | -$587K | 0.83% | 6 |
|
|
2019
Q3 | $9.82M | Sell |
122,113
-16,687
| -12% | -$1.34M | 0.58% | 38 |
|
|
2019
Q2 | $10.1M | Buy |
138,800
+63,722
| +85% | +$4.62M | 0.6% | 41 |
|
|
2019
Q1 | $7.02M | Buy |
+75,078
| New | +$7.02M | 0.4% | 92 |
|
|
2017
Q4 | – | Sell |
-237,626
| Closed | -$27.9M | – | 530 |
|
|
2017
Q3 | $27.9M | Sell |
237,626
-57,474
| -19% | -$6.75M | 0.92% | 3 |
|
|
2017
Q2 | $23.5M | Buy |
+295,100
| New | +$23.5M | 0.95% | 19 |
|
|
2014
Q1 | – | Sell |
-5,804
| Closed | -$373K | – | 1291 |
|
|
2013
Q4 | $373K | Buy |
+5,804
| New | +$373K | 0.04% | 486 |
|